Finch Therapeutics and Crestovo announced the successful completion of a merger, creating a leading, fully integrated microbiome company. The new entity, Finch Therapeutics Group, combines Crestovo's extensive IP assets and late-stage candidate for recurrent C. difficile infections, CP101, an oral Full-Spectrum Microbiota product, with Finch's commercial-scale manufacturing capabilities, discovery platform for developing Rationally-Selected Microbiotaand significant product pipeline. The new company is headquartered in Somerville and led by Chief Executive Officer Mark Smith, Ph.D., previously Finch's President and Chief Executive Officer, and Chief Operating Officer Joseph Lobacki, previously Chief Operating Officer and interim CEO of Crestovo.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.8 USD | -9.09% | -7.22% | -50.14% |
1st Jan change | Capi. | |
---|---|---|
-50.14% | 2.89M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- FNCH Stock
- News Finch Therapeutics Group, Inc.
- Finch Therapeutics and Crestovo Announce Management Appointments to Finch Therapeutics Group